•  
  •  
  •  
  •  

2026-08-09 15:42:46

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  Laboratories

Research

  • Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY
  • BUY Ipca Laboratories - Q4FY22 Result Update - Weak exports; gradual recovery

IPO News

  • Ambey Laboratories Ltd IPO to open for subscription on July 4, 2024
  • Valiant Laboratories Ltd to raise funds through IPO

Stock Report

  • Divi's Laboratories Reports Strong Q1 FY27 Results: Consolidated PAT Soars 65% YoY to ₹902 Crore
  • Dr. Reddy's Laboratories Receives U.S. FDA Approval for Rituximab Biosimilar
  • Dr. Reddy's Laboratories Reports Q1 FY27 Results: Net Profit Stands at ₹435 Crore Amid North America Softness; Sequential Earnings Surge 97%
  • Morepen starts commercial supplies under its Rs. 825 crore CDMO mandate
  • Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States
  • Alkem Laboratories becomes first in India to launch semaglutide in single-shot pre-filled syringes at price starting INR350
  • Morepen Labs Q4 Net Profit Rises 69%
  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • Caplin Point Laboratories Ltd Q4 FY2026 consolidated PAT higher at Rs. 170.11 crores
  • Dr. Reddy's Laboratories Limited recommends final dividend of Rs. 8
  • Neuland Laboratories Ltd recommends final dividend of Rs. 34
  • Dr. Reddys Laboratories Ltd consolidated Q4 FY2025-26 PAT slides to Rs. 220.1 crores
  • Neuland Laboratories Ltd consolidated Q4 FY26 PAT surges to Rs. 212.67 crores
  • US FDA Inspection at Alkem Laboratories Ltd's CRO facility located at Taloja
  • Dr. Reddy's and Nestlé Health Science strengthens presence in diabetes & obesity nutrition space with Celevida® GLP+ launch
  • Auro Laboratories Ltd receives Certification of Substances Department from EDQM
  • Auro Laboratories Ltd receives Certificate of GMP Compliance of a Manufacturer from Swissmedic
  • Caplin Steriles Ltd gets USFDA approval for Calcium Gluconate Injection
  • US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Amaliya, Daman
  • Colinz Laboratories Ltd Q4 FY2026 PAT up at Rs. 17.12 lakhs
  • OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection
  • Morepen Secures Fourth Consecutive USFDA Inspection with Zero Observations
  • Unichem Pharmaceuticals (USA) Issues Voluntary Recall of Buspirone Hydrochloride Tablets
  • Alkem launches A to Z Daily, an everyday multivitamin supplement for body and mind

Industry News

  • Hamdard invests in SIG's aseptic carton technology to meet diverse consumer demands

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025